AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 291 min read$VRXA

Hosseinion Warren purchased $10K of VRXA

Hosseinion Warren purchased 6,024 shares of Veraxa Biotech AG (VRXA) at $1.67 on 2026-09-10.

Original reporting
SEC EDGAR · Hosseinion Warren
Published Sep 29, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$VRXA
Neutral
high confidence
Mentioned
$VRXA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VRXANeutralLow
01

Why it matters

The $10K purchase is a minor insider buy, offering limited actionable insight for traders.

02

Market read

A small insider purchase with minimal market impact; primarily of interest to shareholders monitoring insider activity.

03

What to watch

Potential upcoming corporate actions or clinical data releases that may have prompted the insider to buy.

Relevance 4/10Novelty 4/10Timing: filing posted after market close on 2026‑09‑29

Background

SEC Form 4 filings disclose insider transactions; they are primary sources for insider activity.

Company-level read

Ticker impact

$VRXANeutralHigh confidence
Context

Director Hosseinion Warren bought 6,024 shares at $1.67 each, a $10K open‑market purchase disclosed on Form 4.

Expected impact

slight upward pressure as market prices in insider confidence

Evidence & confidence

The transaction is modest ($10K) and unlikely to move the stock materially; any impact would be limited to a minor positive bias.

Market effects

Sector

None; the purchase is company‑specific and does not affect the biotech sector broadly.

Regional

None; the filing is a routine US SEC disclosure.

Global

None

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a confidence signal.

Key entities

  • Company
    Veraxa Biotech AG

    Biotech firm listed on Nasdaq under ticker VRXA.

  • Insider
    Hosseinion Warren

    Director of Veraxa Biotech AG who made the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

VRXA insider trading history →

Related articles

JUL 10
$VRXAMed

VERAXA Biotech AG: VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister

VERAXA Biotech AG (NASDAQ: VRXA) appointed Carl von Halem as interim CFO, effective immediately, succeeding Torsten Bürgermeister. The company said it is in the final stages of discussions with a successor and will update the market later. The release cites von Halem’s prior CFO role at Xlife Science and other life-sciences experience.

finanznachrichten.de2 min
OCT 7
$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $2.2M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 103,684 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $20.92 ($20.80–$21.09, $2.17M total) across 3 trades over 2026-10-02 to 2026-10-06. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Zolezzi William (10% owner), Divisadero Street Partners, L.P. (10% owner) and Divisadero Street Capital, LLC (10% owner).

SEC EDGAR1 min